Por: Time Health January 19, 2023
Moderna has become a well-known name thanks to its highly effective COVID-19 vaccine, based on mRNA technology. But even before the pandemic hit, the company was developing an mRNA-based vaccine against another scourge, respiratory syncytial virus (RSV), which primarily affects infants and the elderly. In a release issued on Jan. 17, the Massachusetts-based company said an early look at data from the late-stage trial of its RSV vaccine shows... + full article
Ars Technica USA Science January 19, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 18, 2023 8:54 pm UTC Share this story Moderna's mRNA-based vaccine against RSV (respiratory syncytial (sin-SISH-uhl) virus) was effective at preventing disease in older adults, according to preliminary,... + más
Moderna Says Its RSV Vaccine Trial Was a Success. A Clash With Pfizer and GSK Looms. | MarketWatch
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
MarketWatch USA Business January 18, 2023
(ticker: MRNA) said Tuesday its experimental messenger RNA-based RSV vaccine, known as mRNA-1345, was 83.7% effective at preventing less severe disease in adults aged 60 and above, and 82.4% effective at preventing more severe disease. The company only released topline results,... + más
GSK vaccine for older adults granted FDA priority review | Fox Business
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC
Forbes USA Business November 29, 2022
Getty Images Key Takeaways Moderna became a household name for creating one of the first COVID-19 vaccines, helping to loosen up pandemic restrictions globally. Moderna’s stock went up during the pandemic for apparent reasons as countries were scrambling to purchase mass... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
WPLG Local 10 USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals each fall.The preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be... + más
Strong RSV vaccine data lifts hopes after years of futility | ABC News
ABC News USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.The preliminary results buoy hope that after decades of failure and frustration, against RSV may... + más
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
10 WBNS USA Health November 01, 2022
NEW YORK — shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals each fall. The preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be... + más
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |